[1] Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis, 2021,5(1):1-8. [2] Dong Z, Abbas MN, Kausar S, et al. Biological functions and molecular mechanisms of antibiotic tigecycline in the treatment of cancers. Int J Mol Sci, 2019, 20(14):3577-3582. [3] Yang M, Gao H, Wang X, et al. Tigecycline treatment in a liver transplant infant with carbapenem-resistant Escherichia Coli infection: case report. Medicine (Baltimore), 2019, 98(39):339-345. [4] Chen F, Shen C, Pang X, et al. Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: A retrospective study. Transpl Infect Dis, 2020, 22(1):199-205. [5] Meßner M, Schmitt S, Ardelt MA, et al. Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma. FASEB J, 2020, 34(9):11860-11882. [6] 朱曼, 陈翠玉, 郭代红, 等. 499例住院患者替加环素处方行为分析. 中华医院感染学杂志, 2018, 28(17):2611-2614. [7] Alraish R, Wicha SG, Frey OR, et al. Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx). Ann Intensive Care, 2020, 10(1):106-111. [8] 茅益民, 刘晓琳, 陈成伟. 2013年美国FDA药物性肝损伤指南介绍-医药研发企业上市前的临床评估. 肝脏, 2013, 18(5):325-330. [9] Shariati A, Dadashi M, Chegini Z, et al. The global prevalence of daptomycin, tigecycline, quinupristin/dalfopristin, and linezolid-resistant staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis. Antimicrob Resist Infect Control, 2020, 9(1):56-61. [10] Wang J, Pan Y, Shen J, et al. The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob, 2017, 16(1):24-30. [11] Wang L, Liu D, Lyu Y, et al. Novel plasmid-mediated tet(x5) gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinicalAcinetobacter Baumannii isolate. Antimicrob Agents Chemother, 2019, 64(1):1326-1329. [12] Gong J, Su D, Shang J, et al. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: a meta-analysis. Medicine (Baltimore), 2019, 98(38):7091-9097. [13] Bishop EJ, Tiruvoipati R, Metcalfe J, et al. The outcome of patients with severe and severe-complicated clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study. Intern Med J, 2018, 48(6):651-660. [14] 张镭, 谭玲, 陆进. 超说明书用药专家共识.药物不良反应杂志, 2015, 17(2):101-103. [15] Lyu Q, Deng Y, Zhu X, et al. Effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment of multi-drug resistantAcinetobacter Baumannii pulmonary infection. J Coll Physicians Surg Pak, 2020, 30(3):332-334. [16] Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine (Baltimore), 2018, 97(38):167-185. [17] Hughes S, Chin HY, Heard KL, et al. Once-daily tigecycline for outpatient parenteral antibiotic therapy: a single-centre observational study. JAC Antimicrob Resist, 2019, 1(3):85-92. [18] Lyu L, Wan M, Wang C, et al. Emergence of a plasmid-encoded resistance-nodulation-division efflux pump conferring resistance to multiple drugs, including tigecycline, in Klebsiella Pneumoniae. M Bio, 2020, 11(2):2930-2939. [19] 程刚英, 程彪, 周庆, 等. 替加环素致重度肝损伤1例. 中国药物应用与监测, 2018, 15(6):66-68. [20] Zhang L, Pan L, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Ther, 2020, 37(3):1049-1064. |